잠시만 기다려 주세요. 로딩중입니다.

The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies

Molecules and Cells 2020년 43권 2호 p.145 ~ 152
 ( Yokota Asumi ) - Cincinnati Children’s Hospital Medical Center Division of Pathology and Experimental Hematology and Cancer Biology

 ( Huo Li ) - Cincinnati Children’s Hospital Medical Center Division of Pathology and Experimental Hematology and Cancer Biology
 ( Lan Fengli ) - Cincinnati Children’s Hospital Medical Center Division of Pathology and Experimental Hematology and Cancer Biology
 ( Wu Jianqiang ) - Cincinnati Children’s Hospital Medical Center Division of Pathology and Experimental Hematology and Cancer Biology
 ( Huang Gang ) - Cincinnati Children’s Hospital Medical Center Division of Pathology and Experimental Hematology and Cancer Biology

Abstract


RUNX1 plays an important role in the regulation of normal hematopoiesis. RUNX1 mutations are frequently found and have been intensively studied in hematological malignancies. Germline mutations in RUNX1 cause familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML). Somatic mutations of RUNX1 are observed in various types of hematological malignancies, such as AML, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML), and congenital bone marrow failure (CBMF). Here, we systematically review the clinical and molecular characteristics of RUNX1 mutations, the mechanisms of pathogenesis caused by RUNX1 mutations, and potential therapeutic strategies to target RUNX1-mutated cases of hematological malignancies.

키워드

clinical incidence and prognosis; pathogenesis; RUNX1 mutations; targeted therapy
원문 및 링크아웃 정보
 
등재저널 정보